Abstract:CNS germ cell tumors (GCTs) preferentially occur in pediatric and adolescent patients. GCTs are located predominantly in the neurohypophysis and the pineal gland. Histopathologically, GCTs are broadly classified into germinomas and non-germinomatous GCTs (NGGCTs). In general, germinoma responds well to chemotherapy and radiation therapy, with a 10-year overall survival (OS) rate of approximately 90%. In contrast, NGGCTs have a less favorable prognosis, with a five-year OS of approximately 70%. Germinomas are typically treated with platinum-based chemotherapy and whole-ventricular radiation therapy, while mature teratomas can be surgically cured. Other NGGCTs require intensive chemotherapy with radiation therapy, including whole brain or craniospinal irradiation, depending on the dissemination status and protocols. Long-term treatment-related sequelae, including secondary neoplasms and cerebrovascular events, have been well recognized. These late effects have a tremendous impact in later life, especially since patients are mostly affected in childhood or young adults. Intending to minimize the treatment burden on patients, the identification of biomarkers for treatment stratification and evaluation of treatment response is of critical importance. Recently, tumor cell content in germinomas has been shown to be closely related to prognosis, suggesting that cases with low tumor cell content may be safely treated with a less intensive regimen. Among the copy number alterations, the 12p gain is the most prominent and has been shown to be a negative prognostic factor in NGGCTs. MicroRNA clusters (mir-371-373) were also revealed to be a hallmark of GCTs, demonstrating the potential for the application of liquid biopsy in the diagnosis and detection of recurrence. Recurrent mutations have been detected in the MAPK or PI3K pathways, most typically in KIT and MTOR and low genome-wide methylation has been demonstrated in germinoma; this most likely reflects the cell-of-origin primordial germ cells for this tumor type. These alterations can also be leveraged for liquid biopsies of cell-free DNA and may potentially be targeted for treatment in the future. Advancements in basic research will be translated into clinical practice and can directly impact patient management. Additional understanding of the biology and pathogenesis of GCTs will lead to the development of better-stratified clinical trials, ultimately resulting in improved treatment outcomes and a reduction in long-term treatment-related adverse effects.

Glioneuronal and neuronal tumors: A perspective

Imaging of pediatric glioneuronal and neuronal tumors

Neuro-oncology Treatment Strategies for Primary Glial Tumors

The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low‐grade gliomas and glioneuronal tumors

Biomarkers for risk-based treatment modifications for CNS germ cell tumors: Updates on biological underpinnings, clinical trials, and future directions

The neurobiology of gliomas: from cell biology to the development of therapeutic approaches

The Clinical and Molecular Landscape of Rosette-Forming Glioneuronal Tumors

Glioneuronal Tumor with ATRX Alteration, Kinase Fusion and Anaplastic Features (GTAKA): a Molecularly Distinct Brain Tumor Type with Recurrent NTRK Gene Fusions

CNS Germ Cell Tumors: Molecular Advances, Significance in Risk Stratification and Future Directions

Neurooncology: 2024 update

Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline

MPC-17 2021 WHO Classification of Tumors of the CNS, 5th ed

MAPK pathway alterations in polymorphous low-grade neuroepithelial tumor of the young: diagnostic considerations

Novel insights toward diagnosis and treatment of glioneuronal and neuronal tumors in young adults

Glial Malignancies

Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component

10006-PEDT-1 PEDIATRIC LOWER GRADE GLIOMA SURGERY IN THE ERA OF GENOMIC MEDICINE

Biom-02. A High-Grade Glioma, Not Elsewhere Classified In An Older Adult With Discordant Genetic And Epigenetic Analyses

Path-06. Translation Into Clinical Practice Of The G1-G7 Molecular Subgroup Classification Of Glioblastoma

A High-Grade Glioma, Not Elsewhere Classified in an Older Adult with Discordant Genetic and Epigenetic Analyses

Genetic Alterations in Uncommon Low-Grade Neuroepithelial Tumors: BRAF , FGFR1 , and MYB Mutations Occur at High Frequency and Align with Morphology